Cabergoline is a dopamine agonist with few adverse effects and is  generally well tolerated. One study compared cabergoline at a dose of 0.5 mg weekly for 6 doses vs.0.5 mg weekly for 6 doses versus Diphereline (GnRH agonist) (35) . The main findings were that in the cabergoline group there was a reduction rate of fibrotic fibrous reduction rate of fibroid volume from 46 to 53% while in the Diphereline group the reduction was 21 to 53%. Diphereline group the reduction ranged from 21 to 97%. In addition, the cabergoline group had fewer adverse effects. An RCT published in 2016 compared the use of cabergoline 0.5mg orally weekly for 3 months versus no treatment (36) . Treatment with cabergoline was associated with improvement in pain, less bleeding, decrease in uterine size as well as myoma diameter. The no treatment treatment group presented a decrease in hemoglobin levels.